BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services
BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining BiondVax’s core focus of NanoAb therapies for significant indications like COVID-19, psoriasis, asthma, and more BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment…